Related Experiment Video

Updated: May 12, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

Matthieu Schoenhals1, Alboukadel Kassambara, Jean-Luc Veyrune

  • 1INSERM, U1040, Montpellier, France.

Haematologica
|April 16, 2013
PubMed

Insights

Krüppel-like factor 4 (KLF4) acts as a cell cycle inhibitor in multiple myeloma, reducing proliferation. Its expression also increases resistance to chemotherapy, highlighting its complex role in the disease.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Krüppel-like factor 4 (KLF4) is a transcription factor with dual roles in cell proliferation and cancer.
  • Its function in multiple myeloma (MM) biology, particularly its expression patterns and effects on cell cycle and drug resistance, remains incompletely understood.

Purpose of the Study:

  • To analyze KLF4 gene expression in multiple myeloma.
  • To investigate the functional role of KLF4 in MM cell lines, focusing on cell cycle regulation and drug resistance.

Main Methods:

  • Gene expression analysis of KLF4 in primary MM cells and cell lines using Affymetrix microarrays.
  • Generation of conditional KLF4-expressing MM cell lines.
  • Assessment of cell cycle progression and apoptosis.
  • Analysis of KLF4 expression in relation to MM prognostic groups and gene translocations.
  • Evaluation of KLF4's impact on melphalan resistance.

Main Results:

  • KLF4 expression is reduced in most primary MM cells compared to normal plasma cells and is silenced in MM cell lines due to promoter methylation.
  • Conditional KLF4 expression induces G1 cell cycle blockade, dependent on p53 pathway status, and increases resistance to melphalan.
  • KLF4 expression is associated with both poor (MS group, t(4;14)) and good (CD-1 group, t(11;14) or t(6;14)) prognostic groups.

Conclusions:

  • KLF4 plays a critical role in controlling the cell cycle in multiple myeloma.
  • KLF4 expression contributes to the resistance of myeloma cells to alkylating agents like melphalan.
  • KLF4's dual role as a cell cycle inhibitor and enhancer of drug resistance presents a complex therapeutic target in multiple myeloma.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...